VIRI Moving IMC-2 into Phase 2 Program in Long COVID
| VIRIDelisted Stock | USD 3.95 0.00 0.00% |
Under 55% of Virios Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Virios Therapeutics Llc suggests that many traders are impartial regarding Virios Therapeutics' prospects. Virios Therapeutics' investing sentiment shows overall attitude of investors towards Virios Therapeutics Llc.
Virios |
By David Bautz, PhD NASDAQVIRI READ THE FULL VIRI RESEARCH REPORT Business Update IMC-2 to be Developed as Treatment for Long COVID In January 2024, Virios Therapeutics, Inc. announced alignment with the U.S. Food and Drug Administration on the requirements for advancing IMC-2 as a treatment for Long COVID as well as the companys intention to
Read at finance.yahoo.com
 |
Virios Therapeutics Fundamental Analysis
We analyze Virios Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virios Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virios Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Virios Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Virios Therapeutics Llc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Virios Therapeutics stock to make a market-neutral strategy. Peer analysis of Virios Therapeutics could also be used in its relative valuation, which is a method of valuing Virios Therapeutics by comparing valuation metrics with similar companies.
Peers
Virios Therapeutics Related Equities
| CYTO | Altamira Therapeutics | 7.50 | ||||
| IMMX | Immix Biopharma | 7.11 | ||||
| PHIO | Phio Pharmaceuticals | 3.03 | ||||
| RNAZ | Transcode Therapeutics | 2.94 | ||||
| ZURA | Zura Bio | 1.67 | ||||
| REVB | Revelation Biosciences | 1.33 | ||||
| ICU | LMF Acquisition | 1.57 | ||||
| SONN | Sonnet Biotherapeutics | 2.28 | ||||
| ZVSA | ZyVersa Therapeutics | 3.60 | ||||
| CNSP | Cns Pharmaceuticals | 8.33 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Virios Stock
If you are still planning to invest in Virios Therapeutics Llc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virios Therapeutics' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |